DE60236446D1 - Glutation vorlaeufer zur behandlung von neuropsychiatrisschen krankheiten - Google Patents
Glutation vorlaeufer zur behandlung von neuropsychiatrisschen krankheitenInfo
- Publication number
- DE60236446D1 DE60236446D1 DE60236446T DE60236446T DE60236446D1 DE 60236446 D1 DE60236446 D1 DE 60236446D1 DE 60236446 T DE60236446 T DE 60236446T DE 60236446 T DE60236446 T DE 60236446T DE 60236446 D1 DE60236446 D1 DE 60236446D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- nervous system
- central nervous
- present
- glutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title abstract 7
- 238000011282 treatment Methods 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 108010024636 Glutathione Proteins 0.000 abstract 3
- 210000003169 central nervous system Anatomy 0.000 abstract 3
- 229960003180 glutathione Drugs 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000004060 metabolic process Effects 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32506101P | 2001-09-27 | 2001-09-27 | |
| PCT/AU2002/001320 WO2003026684A1 (en) | 2001-09-27 | 2002-09-26 | Modulation of physiological processes and agents useful for same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60236446D1 true DE60236446D1 (de) | 2010-07-01 |
Family
ID=23266273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60236446T Expired - Lifetime DE60236446D1 (de) | 2001-09-27 | 2002-09-26 | Glutation vorlaeufer zur behandlung von neuropsychiatrisschen krankheiten |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20050032708A1 (de) |
| EP (1) | EP1438063B1 (de) |
| JP (3) | JP4684553B2 (de) |
| AT (1) | ATE468129T1 (de) |
| AU (1) | AU2002333018B2 (de) |
| CA (1) | CA2461703C (de) |
| DE (1) | DE60236446D1 (de) |
| DK (1) | DK1438063T3 (de) |
| ES (1) | ES2346859T3 (de) |
| WO (1) | WO2003026684A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040057983A1 (en) * | 2002-09-25 | 2004-03-25 | David Schmidt | Biomolecular wearable apparatus |
| US20050070607A1 (en) * | 2003-08-19 | 2005-03-31 | James Andrus | N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions |
| WO2008049157A1 (en) * | 2006-10-23 | 2008-05-02 | The Mental Health Research Institute Of Victoria | Combination therapy |
| US7829709B1 (en) * | 2007-08-10 | 2010-11-09 | Marquette University | Cysteine prodrugs to treat schizophrenia and drug addiction |
| IL188681A0 (en) * | 2008-01-09 | 2008-12-29 | Amino Acid Solutions Inc | Pharmaceutical compositions and methods utilizing a d-amino acid |
| CA2714226C (en) * | 2008-02-07 | 2017-03-28 | Marquette University | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings |
| US8602961B2 (en) | 2008-05-15 | 2013-12-10 | Lifewave Products Llc | Apparatus and method of stimulating elevation of glutathione levels in a subject |
| WO2010132864A1 (en) * | 2009-05-15 | 2010-11-18 | Intermune, Inc. | Methods of treating hiv patients with anti-fibrotics |
| US8355927B2 (en) | 2010-11-05 | 2013-01-15 | Genomind, Llc | Neuropsychiatric test reports |
| US20120041066A1 (en) * | 2010-08-16 | 2012-02-16 | Lombard Jay L | Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways |
| US20120270860A1 (en) * | 2011-04-19 | 2012-10-25 | Gihyun Yoon | Methods for treating or preventing alcohol-related disorders or craving-related disorders |
| US10369186B2 (en) | 2012-10-30 | 2019-08-06 | Kyowa Hakko Bio Co., Ltd. | Method of treating decline in brain function comprising coadministration of citrulline and glutathione |
| JP6691044B2 (ja) | 2013-11-08 | 2020-04-28 | プロメンテイス・フアーマシユーテイカルズ・インコーポレイテツド | 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物 |
| US20170246148A1 (en) * | 2014-09-15 | 2017-08-31 | Sound Pharmaceuticals Incorporated | Methods and Compositions for Treating Psychotic Disorders |
| EP3858344A4 (de) * | 2018-09-28 | 2022-07-06 | Keio University | Marker zur bewertung der empfindlichkeit gegen ein kombinationsmittel gegen krebs |
| FR3119093B3 (fr) * | 2021-01-27 | 2023-02-10 | Nestle Sa | Compositions et procedes pour une utilisation dans l’augmentation de la performance motivationnelle |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5922765A (en) * | 1996-01-18 | 1999-07-13 | Fleming & Company, Pharmaceuticals | Methods and compositions for the prevention and treatment of muscle cramps and improving muscular strength |
| US5874468A (en) * | 1996-12-26 | 1999-02-23 | Yissum | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US6149925A (en) * | 1998-11-05 | 2000-11-21 | Color Access, Inc. | Topical compositions for enhancing glutathione production |
| US6329430B1 (en) * | 1999-08-18 | 2001-12-11 | Thomas Jefferson University | Modulation of N-methyl-D-aspartate receptor responses with S-substituted derivatives of glutathione |
| US20020002146A1 (en) * | 2000-02-11 | 2002-01-03 | Halevie-Goldman Brian D. | Compositions and methods for the production of S-adenosylmethionine within the body |
| US20020002136A1 (en) * | 2000-06-28 | 2002-01-03 | Hebert Rolland F. | Salts of glutathione |
| WO2002002190A2 (en) * | 2000-07-05 | 2002-01-10 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
| GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| GB2368339B (en) * | 2000-10-26 | 2002-09-18 | Yissum Res Dev Co | Complex incorporating a plurality of antioxidants |
-
2002
- 2002-09-26 DE DE60236446T patent/DE60236446D1/de not_active Expired - Lifetime
- 2002-09-26 AU AU2002333018A patent/AU2002333018B2/en not_active Ceased
- 2002-09-26 DK DK02799377.3T patent/DK1438063T3/da active
- 2002-09-26 WO PCT/AU2002/001320 patent/WO2003026684A1/en active Application Filing
- 2002-09-26 EP EP02799377A patent/EP1438063B1/de not_active Revoked
- 2002-09-26 AT AT02799377T patent/ATE468129T1/de not_active IP Right Cessation
- 2002-09-26 CA CA2461703A patent/CA2461703C/en not_active Expired - Fee Related
- 2002-09-26 ES ES02799377T patent/ES2346859T3/es not_active Expired - Lifetime
- 2002-09-26 JP JP2003530319A patent/JP4684553B2/ja not_active Expired - Fee Related
- 2002-09-26 US US10/491,061 patent/US20050032708A1/en not_active Abandoned
-
2010
- 2010-05-27 JP JP2010121582A patent/JP2010215646A/ja not_active Withdrawn
-
2012
- 2012-11-09 US US13/673,327 patent/US20130065961A1/en not_active Abandoned
-
2013
- 2013-07-18 JP JP2013149286A patent/JP5736421B2/ja not_active Expired - Fee Related
-
2018
- 2018-02-23 US US15/903,559 patent/US20180177839A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2346859T3 (es) | 2010-10-21 |
| US20180177839A1 (en) | 2018-06-28 |
| ATE468129T1 (de) | 2010-06-15 |
| JP4684553B2 (ja) | 2011-05-18 |
| CA2461703C (en) | 2011-04-05 |
| WO2003026684A1 (en) | 2003-04-03 |
| US20050032708A1 (en) | 2005-02-10 |
| CA2461703A1 (en) | 2003-04-03 |
| JP5736421B2 (ja) | 2015-06-17 |
| DK1438063T3 (da) | 2010-08-30 |
| EP1438063A1 (de) | 2004-07-21 |
| AU2002333018B2 (en) | 2006-08-31 |
| EP1438063B1 (de) | 2010-05-19 |
| JP2005508333A (ja) | 2005-03-31 |
| JP2010215646A (ja) | 2010-09-30 |
| EP1438063A4 (de) | 2006-05-31 |
| US20130065961A1 (en) | 2013-03-14 |
| JP2013234193A (ja) | 2013-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60236446D1 (de) | Glutation vorlaeufer zur behandlung von neuropsychiatrisschen krankheiten | |
| DE69411424D1 (de) | Zur Behandlung von Erkrankungen des Zentralnervensystems verwendbare Benzimidazole | |
| ATE462427T1 (de) | Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren | |
| DE60122767D1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
| ATE544449T1 (de) | Neue verwendung von peptidverbindungen zur behandlung von amyothropher lateralsklerose | |
| ATE307592T1 (de) | Epiallopregnanolon zur behandlung von krankheiten des cns | |
| MXPA04003796A (es) | Tioacetamidas sustituidas. | |
| DE60237635D1 (de) | Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose | |
| DE60027732D1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
| ATE392208T1 (de) | Zusammensetzungen zur prävention und behandlung von erkältung und grippe-ähnlichen symptomen, die cheliertes zink enthalten | |
| ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| ATE447403T1 (de) | Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen | |
| DE60320095D1 (de) | Zusammensetzungen zur behandlung von hauterkrankungen | |
| DE602004023762D1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren | |
| DE60231107D1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
| ATE363474T1 (de) | Benzimidazole zur behandlung sexueller fehlfunktionen | |
| ATE437855T1 (de) | (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit | |
| ATE334693T1 (de) | Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten | |
| MY139368A (en) | Novel cyclohexyl sulphones | |
| ATE304855T1 (de) | Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen | |
| DE60219687D1 (de) | Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems | |
| DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
| ATE298246T1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
| ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| ATE320255T1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent |